Clinical Trial Update: Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) [Phase 1, Phase 2]

View source ↗

Summary

Basket trial update for IDX-1197 in HRR-mutated solid tumors (VASTUS) across Phase 1 and Phase 2, now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• IDX-1197

Snippet

Sponsor: Idience Co., Ltd. | Conditions: Solid Tumors, Homologous Recombination Repair Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED